The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies

Seminars in Cancer Biology

Volumn 21, Issue 5, 2011, Pages 308-312

  Burger, Jan A ^a   Ford, Richard J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BTK; CXCR4; CXCR5; Mantle cell lymphoma (MCL); Microenvironment; PI3 k; SYK

Indexed keywords

AVL 292; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CAL 101; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; FOSTAMATINIB; IPI 145; LYMPHOCYTE PEYER PATCH HEV ADHESION MOLECULE 1; P 142 76; P 505 15; PCI 32765; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL HOMING; CELL INTERACTION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; LYMPHOMA ASSOCIATED MACROPHAGE; MACROPHAGE; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 82555165949     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.006     Document Type: Review

References (62)

1. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
2. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
3. Pighi C., Gu T.L., Dalai I., Barbi S., Parolini C., Bertolaso A., et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cellular Oncology (Dordrecht) 2011, 34:141-153.
4. Castillo R., Mascarenhas J., Telford W., Chadburn A., Friedman S.M., Schattner E.J. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 2000, 14:292-298.
5. Andersen N.S., Larsen J.K., Christiansen J., Pedersen L.B., Christophersen N.S., Geisler C.H., et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000, 96:2219-2225.
6. Kurtova A.V., Tamayo A.T., Ford R.J., Burger J.A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613.
7. Dal Col J., Zancai P., Terrin L., Guidoboni M., Ponzoni M., Pavan A., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008, 111:5142-5151.
8. Rodig S.J., Shahsafaei A., Li B., Mackay C.R., Dorfman D.M. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Human Pathology 2005, 36:1113-1119.
9. Nakamura N., Hase H., Sakurai D., Yoshida S., Abe M., Tsukada N., et al. Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Archive 2005, 447:53-60.
10. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of Immunology 2003, 171:88-95.
11. Pham L.V., Ford R.J. The role of BAFF-R dysregulation in B-lymphoid lineage malignancies. Cell Cycle (Georgetown, Tex.) 2011, 10:189-190.
12. Trentin L., Cabrelle A., Facco M., Carollo D., Miorin M., Tosoni A., et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004, 104:502-508.
13. Burger J.A., Burger M., Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94:3658-3667.
14. Burkle A., Niedermeier M., Schmitt-Graff A., Wierda W.G., Keating M.J., Burger J.A. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007, 110:3316-3325.
15. Sipkins D.A., Wei X., Wu J.W., Runnels J.M., Cote D., Means T.K., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
16. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
17. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine 2004, 351:2159-2169.
18. Farinha P., Masoudi H., Skinnider B.F., Shumansky K., Spinelli J.J., Gill K., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
19. Byers R.J., Sakhinia E., Joseph P., Glennie C., Hoyland J.A., Menasce L.P., et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008, 111:4764-4770.
20. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
21. Herishanu Y., Perez-Galan P., Liu D., Biancotto A., Pittaluga S., Vire B., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2010.
22. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
23. Fu K., Weisenburger D.D., Greiner T.C., Dave S., Wright G., Rosenwald A., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
24. Martinez N., Camacho F.I., Algara P., Rodriguez A., Dopazo A., Ruiz-Ballesteros E., et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research 2003, 63:8226-8232.
25. Rizzatti E.G., Falcao R.P., Panepucci R.A., Proto-Siqueira R., Anselmo-Lima W.T., Okamoto O.K., et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. British Journal of Haematology 2005, 130:516-526.
26. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology 2006, 132:303-316.
27. Cecconi D., Zamo A., Bianchi E., Parisi A., Barbi S., Milli A., et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 2008, 8:4495-4506.
28. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
29. Cohen P.L., Kurtin P.J., Donovan K.A., Hanson C.A. Bone marrow and peripheral blood involvement in mantle cell lymphoma. British Journal of Haematology 1998, 101:302-310.
30. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067-2078.
31. Pittaluga S., Wlodarska I., Stul M.S., Thomas J., Verhoef G., Cassiman J.J., et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995, 26:17-24.
32. Glas A.M., Knoops L., Delahaye L., Kersten M.J., Kibbelaar R.E., Wessels L.A., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. Journal of Clinical Oncology 2007, 25:390-398.
33. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
34. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
35. Burger M., Hartmann T., Krome M., Rawluk J., Tamamura H., Fujii N., et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005.
36. Wekerle H., Ketelsen U.P. Thymic nurse cells - Ia-bearing epithelium involved in T-lymphocyte differentiation?. Nature 1980, 283:402-404.
37. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
38. Cyster J.G., Ansel K.M., Reif K., Ekland E.H., Hyman P.L., Tang H.L., et al. Follicular stromal cells and lymphocyte homing to follicles. Immunology Review 2000, 176:181-193.
39. Junt T., Moseman E.A., Iannacone M., Massberg S., Lang P.A., Boes M., et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007, 450:110-114.
40. Carrasco Y.R., Batista F.D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 2007, 27:160-171.
41. Cyster J.G. B cell follicles and antigen encounters of the third kind. Nature Immunology 2010, 11:989-996.
42. Lwin T., Lin J., Choi Y.S., Zhang X., Moscinski L.C., Wright K.L., et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010, 116:5228-5236.
43. Lwin T., Hazlehurst L.A., Dessureault S., Lai R., Bai W., Sotomayor E., et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007, 110:1631-1638.
44. Durig J., Schmucker U., Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001, 15:752-756.
45. Corcione A., Arduino N., Ferretti E., Raffaghello L., Roncella S., Rossi D., et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clinical Cancer Research 2004, 10:964-971.
46. Terol M.J., Lopez-Guillermo A., Bosch F., Villamor N., Cid M.C., Campo E., et al. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. Journal of Clinical Oncology 1999, 17:1869-1875.
47. Allen C.D., Okada T., Cyster J.G. Germinal-center organization and cellular dynamics. Immunity 2007, 27:190-202.
48. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
49. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
50. Drillenburg P., Pals S.T. Cell adhesion receptors in lymphoma dissemination. Blood 2000, 95:1900-1910.
51. Aguilera N.S., Chu W.S., Andriko J.A., Abbondanzo S.L. Expression of CD44 (HCAM) in small lymphocytic and mantle cell lymphoma. Human Pathology 1998, 29:1134-1139.
52. Drillenburg P., van der Voort R., Koopman G., Dragosics B., van Krieken J.H., Kluin P., et al. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin's lymphomas. The American Journal of Pathology 1997, 150:919-927.
53. Geissmann F., Ruskone-Fourmestraux A., Hermine O., Bourquelot P., Belanger C., Audouin J., et al. Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. The American Journal of Pathology 1998, 153:1701-1705.
54. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
55. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine 2005, 352:804-815.
56. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
57. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:13075-13080.
58. Lannutti B.J., Meadows S.A., Herman S.E., Kashishian A., Steiner B., Johnson A.J., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594.
59. Burger J.A., O'Brien S., Fowler N., Advani R., Sharman J.P., Furman R.R., et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010, 116:32a.
60. Fowler N., Sharman J.P., Smith S.M., Boyd T., Grant B., Kolibaba K.S., et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010, 116:425.
61. Flinn I., Byrd J., Furman R., Brown J., Benson D., Coutre S., et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110 isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood 2009, 114. Abstract 922.
62. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H., Fend F., Jaffe E.S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.